391-94-6Relevant academic research and scientific papers
Chalcone compound with anti-cancer activity as well as preparation method, preparation and application of chalcone compound
-
Paragraph 0032; 0033, (2017/08/30)
The invention discloses a chalcone compound with anti-cancer activity as well as a preparation method, a preparation and application of the chalcone compound. The structure of the chalcone compound with the anti-cancer activity is as shown in the specific
Impact of mono- and disubstitution on the colorimetric dynamic covalent switching chalcone/flavanone scaffold
Muller, Brian M.,Mai, Jesse,Yocum, Reid A.,Adler, Marc J.
, p. 5108 - 5114 (2014/07/08)
The effect of aryl substitution on various aspects of the interconversion of ortho-hydroxychalcones and flavanones has been studied using multiple spectroscopic techniques. Derivatization of the core scaffold predictably alters the midpoint pH of this equilibration process suggesting its viability for application as a functional colorimetric molecular switch.
Solution phase synthesis of a combinatorial library of chalcones and flavones as potent cathepsin v inhibitors
Alvim, Joel,Severino, Richele P.,Marques, Emerson F.,Martinelli, Ariane M.,Vieira, Paulo C.,Fernandes, Joao B.,Da Silva, M. Fatima Das G. F.,Correa, Arlene G.
experimental part, p. 687 - 695 (2010/11/18)
Cathepsin V is a papain-like cysteine protease. It is involved in the control of human T cells (responsible for cell immunity), and presents the largest elastolytic activity among the proteolytic enzymes. Therefore, cathepsin V is a potential molecular ta
HETEROCYCLIC COMPOUNDS THAT BLOCK THE EFFECTS OF ADVANCED GLYCATION END PRODUCTS (AGE)
-
Page/Page column 59, (2010/02/11)
The present invention relates to novel compounds of Formula (Ia) or (Ib), their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. Formula (Ia), or Formula (Ib) in the above formulae L represents Formula (I), Formula (II) or -(CH2)1- Q represents Formula (III), or Formula (IV). The present invention also relates to a process for the preparation of the above said novel compounds, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory responses in tissues, including endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. The present invention also relates to compounds that act as modulators of Perlecan activity and expression. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating heparan sulfate proteoglycans (HSPG) such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as stenosis, restenosis, neointimal hyperplasia, and atherosclerosis. The compounds of Formula (I) are also useful for the treatment and/or prevention of cancer. The types of cancers include melanoma, prostate, leukemia, lymphoma, non-small lung cancers, cancer of the central nervous system, breast, colon, ovarian or renal cancer.
